These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 24374838)

  • 1. MED15, encoding a subunit of the mediator complex, is overexpressed at high frequency in castration-resistant prostate cancer.
    Adler D; Menon R; Braun M; Offermann A; Queisser A; Boehm D; Vogel W; Rüenauver K; Ruiz C; Zellweger T; Svensson M; Andren O; Kristiansen G; Wernert N; Bubendorf L; Kirfel J; Biskup S; Perner S
    Int J Cancer; 2014 Jul; 135(1):19-26. PubMed ID: 24374838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling.
    Offermann A; Vlasic I; Syring I; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Hagedorn S; Behrends J; Nowak M; Merseburger A; Bubendorf L; Kirfel J; Duensing S; Adler D; Perner S
    Oncotarget; 2017 Jan; 8(5):7964-7976. PubMed ID: 27974704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MED12 overexpression is a frequent event in castration-resistant prostate cancer.
    Adler D; Offermann A; Braun M; Menon R; Syring I; Nowak M; Halbach R; Vogel W; Ruiz C; Zellweger T; Rentsch CA; Svensson M; Andren O; Bubendorf L; Biskup S; Duensing S; Kirfel J; Perner S
    Endocr Relat Cancer; 2014 Aug; 21(4):663-675. PubMed ID: 24938407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
    Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
    Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcript Levels of Androgen Receptor Variant 7 and Ubiquitin-Conjugating Enzyme 2C in Hormone Sensitive Prostate Cancer and Castration-Resistant Prostate Cancer.
    Lee CH; Ku JY; Ha JM; Bae SS; Lee JZ; Kim CS; Ha HK
    Prostate; 2017 Jan; 77(1):60-71. PubMed ID: 27550197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling.
    Köhler A; Demir U; Kickstein E; Krauss S; Aigner J; Aranda-Orgillés B; Karagiannidis AI; Achmüller C; Bu H; Wunderlich A; Schweiger MR; Schaefer G; Schweiger S; Klocker H; Schneider R
    Mol Cancer; 2014 Jun; 13():146. PubMed ID: 24913494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
    Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
    Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor.
    Cai Y; Chen M; Gong Y; Tang G; Shu Z; Chen J; Zhou H; He Y; Long Z; Gan Y
    Clin Transl Med; 2024 Jan; 14(1):e1531. PubMed ID: 38214432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
    Wu MJ; Chen CJ; Lin TY; Liu YY; Tseng LL; Cheng ML; Chuu CP; Tsai HK; Kuo WL; Kung HJ; Wang WC
    Theranostics; 2021; 11(16):7779-7796. PubMed ID: 34335964
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of TXNDC5 in castration-resistant prostate cancer-involvement of androgen receptor signaling pathway.
    Wang L; Song G; Chang X; Tan W; Pan J; Zhu X; Liu Z; Qi M; Yu J; Han B
    Oncogene; 2015 Sep; 34(36):4735-45. PubMed ID: 25500540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel AR translational regulator lncRNA LBCS inhibits castration resistance of prostate cancer.
    Gu P; Chen X; Xie R; Xie W; Huang L; Dong W; Han J; Liu X; Shen J; Huang J; Lin T
    Mol Cancer; 2019 Jun; 18(1):109. PubMed ID: 31221168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription.
    Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL
    Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.
    Powell K; Semaan L; Conley-LaComb MK; Asangani I; Wu YM; Ginsburg KB; Williams J; Squire JA; Maddipati KR; Cher ML; Chinni SR
    Clin Cancer Res; 2015 Jun; 21(11):2569-79. PubMed ID: 25754347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
    Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
    Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells.
    Singh JP; Dagar M; Dagar G; Kumar S; Rawal S; Sharma RD; Tyagi RK; Bagchi G
    PLoS One; 2020; 15(9):e0226056. PubMed ID: 32881870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer.
    Han W; Gao S; Barrett D; Ahmed M; Han D; Macoska JA; He HH; Cai C
    Oncogene; 2018 Feb; 37(6):710-721. PubMed ID: 29059155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.